TabletsClinical Overview
Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Adults: Take orally 2 mg to 4 mg three to four times daily with water. Children: 0.1 to 0.2 mg/kg per dose three times daily. Take with or without food.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Skeletal muscle tremor, palpitations, tachycardia, nervousness, headache, muscle cramps. Rare/Severe: Hypokalemia and cardiac arrhythmias.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Inhalation route is strongly preferred over oral tablets due to faster onset (minutes vs hours) and dramatically fewer systemic cardiovascular side effects (tremor, tachycardia). Contraindicated in cardiac arrhythmias and severe coronary insufficiency.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Salbutamol Inhalation 100mcg
Salbutamol / Albuterol Inhalation (100mcg MDI, 200mcg Rotacaps) is the quintessential short-acting selective beta-2 adrenergic receptor agonist (SABA) on the WHO Model List of Essential Medicines. It binds to beta-2 adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase, elevating cyclic AMP, and causing rapid relaxation of bronchial smooth muscle within 3 to 5 minutes, lasting 4 to 6 hours. Indicated for immediate relief of acute bronchospasm in bronchial asthma, acute exacerbations of COPD, and prevention of exercise-induced bronchoconstriction.
Salbutamol Syrup 2mg per 5ml
Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).
Salbutamol Tablets 4 mg
Salbutamol Tablets (2mg, 4mg) and Syrup (2mg/5ml) is an oral selective beta-2 adrenergic receptor agonist on the WHO Model List of Essential Medicines. Relaxes bronchial smooth muscle via adenylyl cyclase activation. Indicated for relief of bronchospasm in asthma and reversible obstructive airway disease when inhalation devices cannot be used (e.g. young children or severely arthritic patients).
Salbutamol 100mcg + Ipratropium 20mcg Inhaler
Salbutamol (100mcg) and Ipratropium Bromide (20mcg Inhaler) combines a short-acting beta-2 agonist (SABA) with a short-acting muscarinic antagonist (SAMA) on the WHO Model List of Essential Medicines. Salbutamol relaxes bronchial smooth muscle via cyclic AMP elevation; ipratropium blocks vagal acetylcholine-mediated bronchoconstriction at muscarinic M3 receptors. This dual-pathway approach produces greater, longer-lasting bronchodilation than either agent alone without added sympathomimetic side effects. Indicated for management of bronchospasm in Chronic Obstructive Pulmonary Disease (COPD) and acute severe asthma exacerbations.